Results 61 to 70 of about 1,137 (206)
Replacing in vivo with in vitro studies can increase sustainability in the development of medicines. This principle has already been applied in the biowaiver approach based on the biopharmaceutical classification system, BCS.
Ann-Christin Jacobsen +4 more
doaj +1 more source
S.2437-2453Drug products containing the antibiotics amoxicillin (500 mg as trihydrate) or doxycycline (200 mg as hyclate or monohydrate) with varying qualitative excipient composition were obtained from the German market and their biopharmaceutical ...
Hofsäss, M.A., Dressman, J.
core +1 more source
Among the methods described for determining the solubility, shake-flask is suitable to evaluate the equilibrium solubility according to the BCS. Nevertheless, experimental conditions related to the shake-flask method are not well described.
Patrícia Fernanda Monteiro +5 more
doaj +1 more source
Human radiolabeled mass balance studies are crucial for comprehensively characterizing the absorption, distribution, metabolism, and excretion (ADME) of investigational drugs, providing essential data for drug development, regulatory evaluation, and product labeling.
Jason Boer +24 more
wiley +1 more source
A biowaiver is accepted by the Brazilian Health Surveillance Agency (ANVISA) for immediate-release solid oral products containing Biopharmaceutics Classification System (BCS) class I drugs showing rapid drug dissolution.
Marcelo Dutra Duque +5 more
doaj +1 more source
Types of Biowaivers: A Discussion
The aim of the present review is to discuss the different types of biowaiver applications. Waiving of In vivo bioequivalence studies is known as biowaiver. Types of biowaiver applications include BCS based biowaiver, well established use application, also known as bibliographical application and Literature based submission.
openaire +1 more source
Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling
ABSTRACT Physiologically based pharmacokinetic (PBPK) modeling is a mechanistic cornerstone of model‐informed drug development (MIDD), providing evidence for regulatory decisions. PBPK models integrate physiological and pharmacological data and have been applied across a plethora of contexts of use, including assessing drug–drug interactions (DDIs ...
Marylore Chenel +6 more
wiley +1 more source
Scientific Opinion on waiving of the dog studies in the regulatory process of agrochemicals approval
Abstract Commission Regulation (EU) No. 283/2013 sets out the data requirements for pesticide active substances and includes short‐term oral toxicity testing in rodents (90‐day rat study) and non‐rodents (90‐day dog study) to support human health hazard assessment for pesticide active substances in the European Union (EU). However, the relevance of the
EFSA Panel on Plant Protection Products and their Residues (PPR) +20 more
wiley +1 more source
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride
S.2654-2675In this monograph, literature data is reviewed to evaluate the feasibility of waiving in vivo bioequivalence testing and instead applying the Biopharmaceutics Classification System (BCS) based methods to the approval of immediate-release solid
Mehta, M. +12 more
core +1 more source
Justification of metformin hydrochloride biowaiver criteria based on bioequivalence study
The Biopharmaceutics Classification System (BCS) represents the framework for predicting the intestinal drug absorption based on its solubility and intestinal permeability. Recent research has lead to the use of in vitro tests to waive additional in vivo
Homšek, Irena +9 more
core +1 more source

